

# Long-Chain Omega-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid and Blood Pressure: A Meta-Analysis of Randomized Controlled Trials

Paige E. Miller,<sup>1</sup> Mary Van Elswyk,<sup>2</sup> and Dominik D. Alexander<sup>3</sup>

## BACKGROUND

Although a large body of literature has been devoted to examining the relationship between eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and blood pressure, past systematic reviews have been hampered by narrow inclusion criteria and a limited scope of analytical subgroups. In addition, no meta-analysis to date has captured the substantial volume of randomized controlled trials (RCTs) published in the past 2 years. The objective of this meta-analysis was to examine the effect of EPA+DHA, without upper dose limits and including food sources, on blood pressure in RCTs.

## METHODS

Random-effects meta-analyses were used to generate weighted group mean differences and 95% confidence intervals (CIs) between the EPA+DHA group and the placebo group. Analyses were conducted for subgroups defined by key subject or study characteristics.

## RESULTS

Seventy RCTs were included. Compared with placebo, EPA+DHA provision reduced systolic blood pressure (−1.52 mm Hg; 95%

confidence interval (CI) = −2.25 to −0.79) and diastolic blood pressure (−0.99 mm Hg; 95% CI = −1.54 to −0.44) in the meta-analyses of all studies combined. The strongest effects of EPA+DHA were observed among untreated hypertensive subjects (systolic blood pressure = −4.51 mm Hg, 95% CI = −6.12 to −2.83; diastolic blood pressure = −3.05 mm Hg, 95% CI = −4.35 to −1.74), although blood pressure also was lowered among normotensive subjects (systolic blood pressure = −1.25 mm Hg, 95% CI = −2.05 to −0.46; diastolic blood pressure = −0.62 mm Hg, 95% CI = −1.22 to −0.02).

## CONCLUSIONS

Overall, available evidence from RCTs indicates that provision of EPA+DHA reduces systolic blood pressure, while provision of ≥2 grams reduces diastolic blood pressure.

**Keywords:** blood pressure; docosahexaenoic acid; eicosapentaenoic acid; fish oil; hypertension; meta-analysis; omega-3; randomized controlled trials; systematic review.

doi:10.1093/ajh/hpu024

Thirty-one percent of Americans are hypertensive, 30% are prehypertensive, and approximately 20% are hypertensive yet unaware of their status.<sup>1,2</sup> Only 47% of those with hypertension are adequately controlled.<sup>1</sup> Prior research shows that diet and lifestyle modifications, including physical activity, sodium reduction, and fish oil supplementation, can reduce blood pressure (BP), enhance antihypertensive drug efficacy, and decrease cardiovascular disease (CVD) risk.<sup>3</sup>

The active ingredients in fish oil considered responsible for its antihypertensive effect are the long-chain omega-3 fatty acids eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3). Although previous

meta-analyses of fish oil supplementation and BP have been published,<sup>4-7</sup> none have been designed with inclusion criteria sufficient to examine the extensive scope of literature available in this active area of investigation. For example, the most recently published meta-analysis excluded trials that examined food sources of EPA and DHA (herein referred to as EPA+DHA) and those that were less than 8 weeks in duration.<sup>7</sup> Therefore, our main objective was to update the state of the science by conducting the most comprehensive meta-analysis of its kind of randomized controlled trials (RCTs) that examined EPA+DHA in relation to BP.

Correspondence: Paige E. Miller ([pmiller@exponent.com](mailto:pmiller@exponent.com)).

Initially submitted November 17, 2013; date of first revision December 24, 2013; accepted for publication January 19, 2014; online publication March 6, 2014.

<sup>1</sup>Center for Epidemiology, Biostatistics, and Computational Biology, Exponent, Inc, Chicago, Illinois; <sup>2</sup>Van Elswyk Consulting, Inc, Longmont, Colorado; <sup>3</sup>Center for Epidemiology, Biostatistics, and Computational Biology, Exponent, Inc, Boulder, Colorado.

© The Author 2014. Published by Oxford University Press on behalf of the American Journal of Hypertension.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

## METHODS

### Literature review

A comprehensive literature search was conducted by the University of Colorado Denver Health Science Library using Ovid/Medline, Embase, and the Cochrane Library. A PubMed search was performed in February 2013 to identify any publications not yet indexed by Ovid/Medline. Literature searches covered studies published from 1946 through February 2013 and published in all languages. Level 1 screening included review of all titles and/or abstracts. Full-text publications of any studies not eliminated at level 1 were retrieved for complete review at level 2 screening. Supplementary literature searches included examining the reference lists of all relevant studies, pertinent review articles, and meta-analyses.

### Eligibility criteria for study selection

Included studies were RCTs that examined the effect of EPA+DHA on BP in nonhospitalized adults (aged  $\geq 18$  years). Eligible outcomes were systolic and diastolic BP values (SBP and DBP, respectively). The exclusion criteria in this review were as follows:

1. Hypertensive subjects treated with BP-lowering medications;
2. Less than 3-week treatment duration;
3. Crossover RCTs with less than a 4-week washout period between treatments;
4. Studies that did not specify the amount of EPA+DHA provided or without required data to be used meta-analytically (all authors of otherwise eligible studies were contacted for missing data); and
5. Studies conducted in populations not representative of the general adult population, including pregnant and nursing women and individuals with preexisting CVD or significant disease process (e.g., renal disease or cancer) or secondary hypertension.

### Data extraction and quality assessment

The following qualitative and quantitative information was extracted from all RCTs: publication year, population demographic characteristics, geographic location, baseline hypertensive status, other relevant baseline health characteristics, medication use, sample size, the specific dose of EPA+DHA, the type of food or supplement, outcome assessment method, and means and SDs for BP outcomes.

### Data synthesis

Random-effects meta-analysis models were used to calculate weighted group mean differences (postintervention minus preintervention), 95% confidence intervals (CIs), and corresponding *P* values for heterogeneity between the EPA+DHA group and the placebo group. The weight of each study was based on the inverse of the variance, which is a measure that accounts for the sample size in each group. The macro-level models included data on all subjects at all dose

levels. Subgroup analyses were conducted to identify potential sources of heterogeneity or between-study variability and to estimate the effect of EPA+DHA according to key study characteristics. Categorical dose-response analyses were performed to discern potential patterns or thresholds of effect. Sensitivity and influence analyses were conducted by evaluating the impact of adding or removing studies based on important study characteristics and outlier status. The relative weight of each study was appreciated for each meta-analysis model to determine the influence that each study had on the overall summary effect. The presence of publication bias was assessed visually by examining a funnel plot measuring the SE as a function of effect size, as well as performing Egger's regression method and the Duval and Tweedie imputation method.<sup>8</sup> All analyses were performed using Comprehensive Meta-Analysis (version 2.2.046; Biostat, Englewood, NJ).

## RESULTS

### Study Characteristics

A flow diagram of the search strategy, including reasons for exclusion, is shown in [Figure 1](#). A total of 70 RCTs<sup>9–78</sup> met all eligibility criteria and were included in the meta-analysis. The main study characteristics are shown in [Table 1](#) (hypertensive populations) and [Table 2](#) (normotensive populations, with 1 prehypertensive population).<sup>17</sup> Ramel *et al.*<sup>63</sup> examined hypertensive and normotensive subjects combined; these data are included in [Table 1](#) but were not meta-analyzed in the subgroup analyses by hypertension status. Approximately 40% of the included RCTs were conducted in North America, with the remaining distributed primarily between Nordic countries (20%), European countries other than the Nordic countries (27%), and Australia (13%). The mean study duration was 69 days, the mean EPA+DHA dose was 3.8 g/day, and sources of EPA+DHA included different types of seafood, EPA+DHA-fortified foods, fish oil, algal oil, and purified ethyl esters. Olive oil was the most commonly used placebo, with the remainder consisting predominately of other vegetable oils (e.g., safflower, corn, and sunflower oils).

### Results from meta-analysis

Meta-analysis results for all analyses are reported in [Table 3](#), and results for selected analyses are illustrated in [Figures 2 and 3](#) and [Supplementary Figures S1 and S2](#).

In the overall meta-analysis model of 93 data points from 70 RCTs, SBP decreased by 1.52 mm Hg (95% CI =  $-2.25$  to  $-0.79$ ) and DBP by 0.99 mm Hg (95% CI =  $-1.54$  to  $-0.44$ ), compared with placebo, after EPA+DHA provision ([Table 3](#); [Supplementary Figures S1 and S2](#)). Studies with multiple entries in the meta-analysis models reflect results presented separately by the authors for different subgroups (e.g., low-dose and high-dose EPA+DHA). In the meta-analysis of hypertensive subjects, significant reductions in SBP ( $-4.51$  mm Hg; 95% CI =  $-6.12$  to  $-2.83$ ) and DBP ( $-3.05$  mm Hg; 95% CI =  $-4.35$  to  $-1.74$ ) were observed ([Figure 2](#)). The meta-analysis of studies among normotensive subjects also found a significant reduction of SBP ( $-1.25$  mm Hg; 95% CI =  $-2.05$  to  $-0.46$ ) and DBP ( $-0.62$  mm Hg; 95%

CI =  $-1.22$  to  $-0.02$ ) (Table 3). The summary estimates were modified by source of EPA+DHA and by study region (Table 3). In the meta-analysis of supplement-only studies, SBP decreased by 1.75 mm Hg (95% CI =  $-2.55$  to  $-0.94$ ) and DBP by 1.11 (95% CI =  $-1.72$  to  $-0.50$ ) after EPA+DHA provision, compared with placebo. Among US-only studies, reductions of 1.78 mm Hg (95% CI =  $-3.33$  to  $-0.23$ ) in SBP and 1.35 mm Hg (95% CI =  $-2.48$  to  $-0.21$ ) in DBP were observed. Because relatively few studies evaluated EPA+DHA as individual fatty acids, there was insufficient statistical power to detect a meaningful difference between EPA and DHA separately on lowering either SBP or DBP.

The subgroup analyses by dose are depicted in Figure 3. There was no clear pattern of dose-response between EPA+DHA and SBP. Significant reductions were observed with doses of 1 to  $<2$  g/d ( $-1.81$ ; 95% CI =  $-3.59$  to  $-0.03$ ) and 3 to  $<4$  g/d ( $-3.85$ ; 95% CI =  $-5.55$  to  $-2.15$ ). No apparent effect on DBP was observed for dose levels  $<2$  g/day, whereas significant reductions were observed for 2 to  $<3$  g/day ( $-1.09$ ; 95% CI =  $-2.08$  to  $-0.11$ ) and 3 to  $<4$  g/day ( $-1.86$ ; 95% CI =  $-2.67$  to  $-1.06$ ).


An examination of potential publication bias indicated a modest proclivity for published studies that found a significant SBP reduction with EPA+DHA provision (Supplementary Figure S3). There was a slight indication of publication bias with a proclivity for publication of results that showed a significant DBP reduction with EPA+DHA provision, which was modified by study region. Non-US studies were more likely to publish findings showing DBP reduction with EPA+DHA provision, whereas US studies

were more likely to publish null findings or an increase in DBP with EPA+DHA provision.

## DISCUSSION

This meta-analysis of RCTs that examined EPA+DHA provision and BP provides the most comprehensive quantitative summary of the evidence to date. Before this meta-analysis, the most recent published meta-analysis<sup>7</sup> excluded studies  $<8$  weeks in duration and those that examined food sources of EPA+DHA. By liberalizing the duration restriction to 3 weeks, including RCTs conducted with EPA+DHA-rich and -fortified foods, and capturing recent RCTs published in the past 2 years, our meta-analysis evaluated an additional 53 studies not included by Campbell *et al.*<sup>7</sup> The considerably larger volume of studies enhanced the statistical power to perform important subgroup analyses by factors such as dose, geographic region, hypertensive status, and source of EPA+DHA.

The results from our analysis demonstrate that EPA+DHA are as effective, and in some cases more effective, than other lifestyle-related interventions, including increasing physical activity and restricting alcohol and sodium,<sup>79</sup> for lowering BP among hypertensive populations not taking antihypertensive medication. These results are consistent with findings from Campbell *et al.*<sup>7</sup> as well as other earlier meta-analyses.<sup>80,81</sup> Lowered systemic vascular resistance through changes in endothelial function is considered a primary mechanism by which EPA+DHA may lower BP.<sup>82</sup> Recent systematic reviews and a meta-analysis of RCTs found improved endothelial function in response to EPA+DHA, particularly among



**Figure 1.** Flow diagram of literature search and selection of randomized controlled trials (RCTs) for meta-analysis of eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and blood pressure.

**Table 1.** Characteristics of the randomized controlled trials in hypertensive study populations<sup>a</sup>

First author	Year	Country	Age, y <sup>b</sup>	Sex, M/F <sup>c</sup>	Duration, d	Intervention type	Intervention regimen				
							Dose, g/d <sup>a</sup>	DHA, g/d	EPA, g/d	DHA+ EPA, g/de	Control
Bonaa <sup>14</sup>	1990	Norway	20–61	156 (M+F)	70	Fish oil (EE)	6	1.8	3.2	5.1	Corn oil
Hill <sup>38</sup>	2007	Australia	25–65	28/53	84	Fish oil	6	1.6	0.4	1.9	Sunflower oil
Hughes <sup>39</sup>	1990	United States	NR	26/0	30	Fish oil	10	1.5	3.5	5.0	Wheat germ oil
Knapp <sup>41</sup>	1989	United States	30–71	36/0	28	Fish oil	50	6.0	9.0	15.0	Safflower oil
							10	1.2	1.8	3.0	Mixed vegetable oils
Landmark <sup>42</sup>	1993	Norway	33–64	18/0	28	Fish oil (EE)	10	2.8	1.8	4.8	Olive oil
Levinson <sup>43</sup>	1990	United States	18–75	17 (M+F)	42	Fish oil	50	6.0	9.0	15.0	Vegetable oil
Meland <sup>48</sup>	1989	Norway	26–66	40/0	42	Fish oil	20	2.4	3.6	6.4	Olive + corn oil
Munda <sup>54</sup>	1993	Norway	33–64	18/0	28	Fish oil	–	2.8	1.8	4.6	Olive oil
Passfall <sup>60</sup>	1993	Germany	40–61	4/6	42	Fish oil	9	0.9	1.3	2.2	Olive oil
Prisco <sup>61</sup>	1998	Italy	33–57	32/0	120	Fish oil (EE)	4	1.4	2.0	3.6	Olive oil
Radack <sup>62</sup>	1991	United States	≥ 18	19/14	84	Fish oil	6	0.8	1.2	2.0	Safflower oil
Ramel <sup>63,f</sup>	2010	Iceland, Spain, Ireland	20–40	138/186	56	Fish oil	6	–	–	2.1	Sunflower oil
						Cod	64	–	–	1.3	
						Salmon	64	–	–	0.3	
Sagara <sup>65</sup>	2011	United Kingdom	45–59	38/0	35	DHA-enriched bread	2	2.0	0.0	2.0	Olive oil–enriched bread
Steiner <sup>69</sup>	1989	Switzerland	44 (13)	17/11	28	Fish oil	4	0.5	1.1	2.0	Salad oil
Toff <sup>71</sup>	1995	Norway	20–61	50/28	112	Fish oil (EE)	4	–	–	3.4	Corn oil
Wang <sup>77</sup>	2008	China	42 (3)	14/7	56	Fish oil	3	0.4	0.5	0.9	Vegetable oil

Abbreviations: DHA, docosahexaenoic acid; EE, ethyl esters; EPA, eicosapentaenoic acid; F, female; M, male; NR, not reported.

<sup>a</sup> Two study populations (Hughes *et al.* 1990<sup>39</sup> and Steiner *et al.* 1989<sup>69</sup>) were stratified by hypertensive status; therefore, only study characteristics for hypertensives are shown here.

<sup>b</sup> Mean (SD) is shown when range was not provided.

<sup>c</sup> The total sample size is shown plus M+F to indicate both men and women were included when the distribution by sex was not provided.

<sup>d</sup> Dose of entire fish oil supplement or food.

<sup>e</sup> May include small amounts of docosapentaenoic acid.

**Table 2.** Characteristics of the randomized controlled trials in normotensive study populations<sup>a,f</sup> Not included in hypertensive-only meta-analysis because only a portion of the population (32%) was hypertensive

First author	Year	Country	Age, y <sup>b</sup>	Sex, M / F <sup>c</sup>	Duration, d	Intervention type	Intervention regimen				
							Dose, g/d <sup>d</sup>	DHA, g/d	EPA, g/d	DHA+ EPA, g/d <sup>e</sup>	Control
Armstrong <sup>10</sup>	2012	United States	20–59	35/81	42	Fish oil (EE)	5	1.0	2.0	3.0	Corn + soy oil
Atar <sup>11</sup>	2012	Iran	45–65	0/78	56	Fish oil	2	0.5	0.7	1.2	Cornstarch
Bach <sup>12</sup>	1989	United States	31 (9)	16/14	35	Fish oil	6	1.4	1.1	2.5	Fractionated coconut oil
Barcelo-Coblijn <sup>13</sup>	2008	Canada	36–43	50/3	84	Fish oil	0.6	0.1	0.3	0.4	Sunflower oil
							1.2	0.3	0.5	0.8	
Browning <sup>15</sup>	2007	United Kingdom	< 50	0/33	84	Fish oil	–	2.9	1.3	4.2	Oleic + linoleic acid oil
Buckley <sup>16</sup>	2009	Australia	22 (1)	25/0	35	Fish oil	6	1.6	0.4	1.9	Sunflower oil
Carter <sup>17,f</sup>	2012	United States	24 (2)	18/20	56	Fish oil	9	1.1	1.6	2.7	Olive oil
Cazzola <sup>18</sup>	2007	Italy	18–42	100/0	84	Fish oil	3	0.3	1.4	1.6	Corn oil
							6	0.5	2.7	3.2	
							9	0.8	4.1	4.9	
Chin <sup>19</sup>	1993	Australia	18–32	29/0	28	Fish oil	5	0.6	0.9	1.5	Palm + safflower + olive oil
							10	1.2	1.8	2.9	
							20	2.3	3.6	5.9	
Cobiac <sup>20</sup>	1991	Australia	30–60	31/0	35	Salmon + sardines	164	3.0	1.5	4.5	Mixed vegetable oil
							15	1.6	3.0	4.6	
Conquer <sup>21</sup>	1999	Canada	30 (2)	19/0	42	Seal oil	20	1.7	1.3	3.8	Vegetable oil
Croset <sup>22</sup>	1990	France	86 (4)	NR	60	Fish oil (EE)	0.1	0.0	0.1	0.1	Placebo oil (NFS)
Denke <sup>23</sup>	1988	United States	18–60	8/23	28	Fish oil	5	–	–	1.7	Safflower oil
Derosa <sup>25</sup>	2009	Italy	≥18	164/169	180	Fish oil (EE)	3	1.5	0.9	2.4	Sucrose, mannitol and mineral salts
Derosa <sup>24</sup>	2012	Italy	18–75	82/85	180	Fish oil (EE)	3	1.4	1.2	2.6	Sucrose, mannitol and mineral salts
Deslypere <sup>26</sup>	1992	Belgium	21–90	58/0	365	Fish oil	3	0.2	0.8	1.1	Olive oil
							6	0.3	1.6	2.1	
							9	0.5	2.4	3.2	
Dewell <sup>27</sup>	2011	United States	50 (10)	64/36	60	Fish oil	2	0.5	0.7	1.2	Soybean oil
							6	1.5	2.1	3.6	
Dyerberg <sup>28</sup>	2004	Denmark	20–60	87/0	56	Fish oil	12	1.3	2.0	3.3	Palm oil
Finnegan <sup>29</sup>	2003	United Kingdom	25–72	87/63	120	EPA+DHA-enriched margarine	25	0.3	0.2	0.5	Margarine (sunflower + safflower oil-based)

Continued

Table 2. Continued

First author	Year	Country	Age, y <sup>b</sup>	Sex, M / F <sup>c</sup>	Duration, d	Intervention regimen					
						Intervention type	Dose, g/d <sup>d</sup>	DHA, g/d	EPA, g/d	DHA+ EPA, g/d <sup>e</sup>	Control
						EPA+DHA-enriched margarine + fish oil capsules	28	-	-	1.3	Margarine + capsules (both sunflower + safflower oil-based)
Flaten <sup>30</sup>	1990	Norway	35-45	56/0	42	Fish oil	14	2.9	3.6	6.8	Olive Oil
Geelen <sup>31</sup>	2003	Nether-lands	50-70	36/38	84	Fish oil	3.5	0.6	0.7	1.3	Sunflower oil
Ginty <sup>32</sup>	2012	United States	NR	8/26	21	Fish oil	-	0.4	1.0	1.4	Corn oil
Grimsgaard <sup>33</sup>	1998	Norway	36-56	224/0	49	Fish oil (EE)	4	0.0	4.0	4.0	Corn oil
Gustafsson <sup>34</sup>	1996	Sweden	48 (9)	24 (M+F)	21	EPA+DHA-enriched food products	57	-	-	3.2	Sunflower-enriched food products
Hallund <sup>35</sup>	2010	Denmark	40-70	45/0	56	Marine trout	150	2.0	0.9	3.2	Chicken
Harris <sup>36</sup>	2008	United States	21-70	14 /19	112	Fish oil (EE)	23	0.0	1.0	1.0	Soybean oil
Hellsten <sup>37</sup>	1993	Sweden	30-60	40 (M+F)	150	Cod liver oil	6	-	-	2.0	Corn oil
Hughes <sup>39</sup>	1990	United States	NR	26/0	30	Fish oil	10	1.5	3.5	5.0	Wheat germ oil
Kelley <sup>40</sup>	2007	United States	54 (2)	34/0	90	Fish oil	7.5	3.0	-	3.0	Olive oil
Lindqvist <sup>78</sup>	2009	Sweden	35-60	35/0	42	Baked herring	150	-	-	1.2	Baked lean pork + chicken
Lofgren <sup>44</sup>	1993	United States	40-60	23/0	84	Fish oil	20	2.4	3.6	6.0	Safflower oil
Mackness <sup>45</sup>	1994	7 European countries	30-71	55/24	98	Fish oil	4	-	-	3.4	Corn oil
Mak <sup>46</sup>	2009	United States	35-64	8/42	28	Krill oil	2	0.1	0.2	0.3	Olive oil
McVeigh <sup>47</sup>	1994	Ireland	45-61	16/4	42	Fish oil	2	0.2	0.2	0.4	
Mills <sup>50</sup>	1989	Canada	22-34	20/0	28	Fish oil	10	1.2	1.8	3.0	Olive oil
Mills <sup>49</sup>	1990	Canada	19-31	29/0	28	Fish oil	9	1.0	1.6	2.6	Olive oil
Monahan <sup>51</sup>	2004	United States	18-35	10/8	30	Fish oil	4.5	0.5	0.8	1.3	Safflower Oil
Mori <sup>52</sup>	1999	Australia	20-65	56/0	42	Fish oil (EE)	10	2.0	3.0	5.0	Olive Oil
							4	0.0	3.8	3.8	Olive oil
							4	3.7	0.0	3.7	
Mortensen <sup>53</sup>	1983	Denmark	25-40	20/0	28	Fish oil	10	0.5	0.8	1.4	Vegetable oil
Murphy <sup>55</sup>	2007	Australia	20-65	35/39	190	EPA+DHA-enriched foods	-	-	-	1.0	Same foods, without DHA+EPA enrichment
Neff <sup>56</sup>	2010	United States	18-65	15/21	112	Algal oil	5	2.0	0.0	2.0	Corn + soybean oil

Continued

Table 2. Continued

First author	Year	Country	Age, y <sup>b</sup>	Sex, M / F <sup>c</sup>	Duration, d	Intervention type	Intervention regimen				
							Dose, g/d <sup>d</sup>	DHA, g/d	EPA, g/d	DHA+ EPA, g/d <sup>e</sup>	Control
Nestle <sup>57</sup>	2002	United States	40–69	21/17	49	Fish oil (EE)	4	0.1	3.0	3.1	Olive oil
Nordoy <sup>58</sup>	2001	Norway	28–61	32/10	35	Fish oil (EE)	4	2.8	0.2	3.5	Corn oil
Noreen <sup>59</sup>	2012	United States	19–55	14/26	42	Fish oil	2	0.8	0.9	1.7	Corn oil
Ryu <sup>64</sup>	1990	United States	20–39	20/0	28	Fish oil	4	1.0	1.8	3.1	Safflower oil
Sanders <sup>66</sup>	2006	United Kingdom	33 (13)	39/40	28	Fish oil	6	0.9	2.1	3.0	Wheat germ oil
Sjoberg <sup>67</sup>	2010	Australia	53 (17)	17/16	84	Fish oil	4	1.5	0.0	1.5	Olive oil
							2	0.5	0.1	0.7	Sunola oil
							4	1.0	0.2	1.3	
							6	1.6	0.3	2.0	
Stark <sup>68</sup>	2004	Canada	45–70	0/32	28	Fish oil	6	2.8	0.0	2.8	Corn + soy oil
Steiner <sup>69</sup>	1989	Switzer-land	44 (13)	17/11	28	Fish oil	4	0.5	1.1	2.0	Salad oil
Theobald <sup>70</sup>	2007	United Kingdom	45–65	20/19	90	Fish oil	1.5	0.7	0.0	0.7	Olive oil
THPCRG <sup>9</sup>	1992	United States	30–54	245/105	180	Fish oil	6	1.0	1.4	3.6	Olive oil or other placebo
Vakhpova <sup>72</sup>	2011	Israel	50–90	67/63	105	Fish oil	3	0.0	0.0	0.0	Cellulose
Vandongen <sup>73</sup>	1993	Australia	30–60	51/0	84	Fish oil	6	0.9	1.3	2.3	Olive + palm + safflower oils
							12	1.7	2.6	4.7	
Vericel <sup>74</sup>	1999	France	70–83	6/14	42	Fish oil	0.6	0.2	0.0	0.2	Sunflower oil
von Houwelingen <sup>75</sup>	1987	Nether-lands	20–45	82/0	42	Mackarel paste	135	3.0	1.7	4.7	Meat paste
Walser <sup>76</sup>	2008	United States	20–51	14/7	42	Fish oil	10	2.0	3.0	5.0	Safflower oil

Abbreviations: DHA, docosahexaenoic acid; EE, ethyl esters; EPA, eicosapentaenoic acid; NFS, not further specified; NR, not reported; THPCRG, Trials of Hypertension Prevention Collaborative Research Group.

<sup>a</sup> Two study populations (Hughes *et al.*<sup>39</sup> and Steiner *et al.*<sup>69</sup>) were stratified by hypertensive status; therefore, only study characteristics for normotensives are shown here.

<sup>b</sup> Mean (SD) is shown when range was not provided.

<sup>c</sup> The total sample size is shown plus M+F to indicate both men and women were included when the distribution by sex was not provided.

<sup>d</sup> Dose of entire fish oil supplement or food.

<sup>e</sup> May include small amounts of docosapentaenoic acid.

<sup>f</sup> Population includes normotensive and prehypertensive subjects.


**Table 3.** Summary of meta-analysis results

Model	No. of data points	WGMD	Lower 95% CI	Upper 95% CI	<i>P</i> value for heterogeneity
Systolic blood pressure					
All studies <sup>a</sup>	93	-1.52	-2.25	-0.79	0.001
Supplement only	82	-1.75	-2.55	-0.94	0.001
Food only	11	0.10	-1.31	1.50	0.50
US studies	25	-1.78	-3.33	-0.23	0.03
Non-US studies	68	-1.33	-2.16	-0.50	0.007
Duration ≥60 days	41	-1.63	-2.67	-0.59	0.08
Dose 0 to <1 g	12	-2.38	-5.14	0.38	0.009
Dose 1 to <2 g	19	-1.81	-3.59	-0.03	0.47
Dose 2 to <3 g	18	-0.21	-1.85	1.43	0.007
Dose 3 to <4 g	22	-3.85	-5.55	-2.15	0.05
Dose 4 to <5 g	11	-0.86	-1.84	0.13	0.97
Dose ≥5 g	10	-0.36	-2.95	2.23	0.17
Hypertensive subjects	15	-4.51	-6.12	-2.83	0.72
Normotensive subjects	73	-1.25	-2.05	-0.46	0.01
EPA only	7	-4.61	-8.35	-0.86	0.01
DHA only	8	-1.27	-3.37	0.84	0.28
Ethyl ester	15	-2.24	-3.72	-0.76	0.002
Other marine oils	67	-1.45	-2.39	-0.50	0.007
Diastolic blood pressure					
All studies <sup>a</sup>	92	-0.99	-1.54	-0.44	0.00
Supplement only	81	-1.11	-1.72	-0.50	0.00
Food only	11	-0.38	-1.46	0.70	0.75
US studies	24	-1.35	-2.48	-0.21	0.02
Non-US studies	68	-0.88	-1.52	-0.25	0.00
Duration ≥60 days	41	-0.95	-1.56	-0.34	0.31
Dose 0 to <1 g	10	0.04	-1.48	1.56	0.78
Dose 1 to <2 g	21	0.40	-1.10	1.91	0.001
Dose 2 to <3 g	18	-1.09	-2.08	-0.11	0.16
Dose 3 to <4 g	22	-1.86	-2.67	-1.06	0.36
Dose 4 to <5 g	11	-0.59	-1.37	0.19	0.94
Dose ≥5 g	10	-1.97	-3.96	0.02	0.06
Hypertensive subjects	15	-3.05	-4.35	-1.74	0.17
Normotensive subjects	72	-0.62	-1.22	-0.02	0.002
EPA only	5	-0.81	-1.99	-0.37	0.55
DHA only	8	-0.84	-2.29	0.62	0.32
Ethyl ester	16	-0.80	-1.49	-0.11	0.28
Other marine oils	64	-1.20	-2.02	-0.37	0.00


Abbreviations: CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; WGMD, weighted group mean difference.

<sup>a</sup> Includes all studies, regardless of dose, duration, region, hypertensive status, and source of EPA+DHA (supplement or food).





**Figure 2.** Results from meta-analyses of randomized controlled trials examining eicosapentaenoic and docosahexaenoic acids (EPA+DHA) provision and (a) systolic blood pressure and (b) diastolic blood pressure among hypertensive subjects. The squares represent average change in blood pressure in individual randomized controlled trials, or individual trial strata, with 95% confidence intervals (CIs). The diamond represents the pooled summary estimate. Knapp (a) is a higher-dose subgroup, and Knapp (b) is a lower-dose subgroup.



**Figure 3.** Results from meta-analyses of randomized controlled trials examining eicosapentaenoic and docosahexaenoic acids (EPA+DHA) and (a) systolic blood pressure and (b) diastolic blood pressure by EPA+DHA dose category. The circle represents the pooled summary estimate across all studies within each dose category, with 95% confidence intervals (CIs). n indicates the number of data points in each dose category, which may be greater than the number of individual studies.

patients with risk factors for CVD, including hypertension, but not consistently among healthy young and middle-aged subjects.<sup>83,84</sup> This observation may explain the greater response of unmedicated hypertensive subjects when compared with normotensive subjects in our meta-analysis.

The reductions in BP observed in this analysis are not only statistically significant but also are clinically meaningful. Among adults, SBP rises by approximately 0.6 mm Hg per year; among those aged  $\geq 50$  years, the lifetime risk of hypertension is 90%.<sup>85</sup> Furthermore, only 1 mm Hg SBP separates each stage of hypertension. The statistically significant reduction in SBP of 1.25 mm Hg noted among normotensive individuals in our analysis would represent a delay of age-related SBP increase by 2 years and progression from prehypertensive to hypertensive status. The 4.51 mm Hg decrease observed among hypertensive populations not taking antihypertensive medication could prevent an individual from requiring medication to control their hypertension or could help maintain an individual in a lower stage of progressive hypertension. Lowered systemic vascular resistance and BP

can reduce risk of coronary plaque rupture, stroke, and complications of stroke, including related cognitive decline, thus improving clinical outcomes for higher-risk populations.<sup>82</sup>

Overall, there was no clear discernible pattern of a dose-response effect for EPA+DHA on BP, which is similar to findings from past meta-analyses.<sup>7,81,86</sup> Although less data are available that examine EPA+DHA-rich or -fortified food and BP outcomes (n = 8 studies in this meta-analysis), EPA+DHA-rich or -fortified foods were less effective than supplements with regards to lowering BP. It is important to note, however, that there are barriers to frequent fish consumption, which may explain in part the discrepant findings between food and supplement studies. Among the general population, barriers to frequent fish consumption include dislike of taste, unpleasant smell, and “concerns about bones.”<sup>87,88</sup> Five of the 8 food studies in the current meta-analysis required daily consumption of oily fish, including sardines, mackerel, and salmon. Although compliance was not routinely reported among all food studies, von Houwelingen *et al.*,<sup>75</sup> who provided subjects with mackerel, reported compliance of only 78%. In

addition, the researchers noted that a tendency for compliance decreased over the course of the study, as assessed by urinary lithium excretion. Only 3 studies of EPA+DHA–fortified foods (e.g., margarine and bread)<sup>29,55,65</sup> were identified for inclusion in our meta-analysis, which challenges efforts to fully investigate the role of these EPA+DHA sources as part of an overall healthy dietary pattern.

Collectively, the evidence from RCTs indicates that provision of  $\geq 2$  g/d EPA+DHA may reduce both SBP and DBP, with the strongest benefits observed among hypertensive individuals who are not on antihypertensive medication. In addition, a lower dose (between 1 and 2 g/d) may reduce SBP but not DBP. From a clinical and public health perspective, provision of EPA+DHA may lower BP and ultimately reduce the incidence of associated chronic diseases.

## SUPPLEMENTARY MATERIAL

Supplementary materials are available at *American Journal of Hypertension* (<http://ajh.oxfordjournals.org>).

## ACKNOWLEDGMENTS

We acknowledge GOED for their partial support of this research.

## DISCLOSURE

This work was supported by the Global Organization for EPA and DHA Omega-3s (GOED). GOED had no role in the study design or conduct; the acquisition, extraction, management, or analysis of data; the interpretation of research findings; or the writing of the manuscript.

## REFERENCES

- Centers for Disease Control and Prevention. Vital signs: prevalence, treatment, and control of hypertension—United States, 1999–2002 and 2005–2008. *MMWR Morbid Mortal Wkly Rep* 2011; 60:103–108.
- Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. *Circulation* 2012; 125:e2–e220.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; 289:2560–2572.
- Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. *Br J Nutr* 2012; 107:S195–S200.
- Hartweg J, Farmer AJ, Holman RR, Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. *Diabetologia* 2007; 50:250–258.
- Xin W, Wei W, Li X. Effect of fish oil supplementation on fasting vascular endothelial function in humans: a meta-analysis of randomized controlled trials. *PLoS One* 2012; 7:e46028.
- Campbell F, Dickinson HO, Critchley JA, Ford GA, Bradburn M. A systematic review of fish-oil supplements for the prevention and treatment of hypertension. *Eur J Prev Cardiol* 2013; 20:107–120.
- Rothstein H, Sutton A, Borenstein M, eds. *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments*. John Wiley and Sons: Chichester, England, 2005.
- Trials of Hypertension Prevention Collaborative Research Group (THPCRG). The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. *JAMA* 1992; 267:1213–1220.
- Armstrong P, Kelley DS, Newman JW, Staggers FE Sr, Hartiala J, Allayee H, Stephensen CB. Arachidonate 5-lipoxygenase gene variants affect response to fish oil supplementation by healthy African Americans. *J Nutr* 2012; 142:1417–1428.
- Atar MJH, Hajianfar H, Bahonar A. The effects of omega-3 on blood pressure and the relationship between serum visfatin level and blood pressure in patients with type II diabetes. *ARYA Atheroscler* 2012; 8:27–31.
- Bach R, Schmidt U, Jung F, Kiesewetter H, Hennen B, Wenzel E, Schieffer H, Bette L, Heyden S. Effects of fish oil capsules in two dosages on blood pressure, platelet functions, haemorheological and clinical chemistry parameters in apparently healthy subjects. *Ann Nutr Metab* 1989; 33:359–367.
- Barcelo-Coblijn G, Murphy EJ, Othman R, Moghadasian MH, Kashour T, Friel JK. Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3 fatty acid composition: A multiple-dosing trial comparing 2 sources of n-3 fatty acid. *Am J Clin Nutr* 2008; 88:801–809.
- Bönaa KH, Bjerve KS, Straume B, Gram IT, Thelle D. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromsø study. *N Engl J Med* 1990; 795–801.
- Browning LM, Krebs JD, Moore CS, Mishra GD, O'Connell MA, Jebb SA. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. *Diabetes Obes Metab* 2007; 9:70–80.
- Buckley JD, Burgess S, Murphy KJ, Howe PRC. DHA-rich fish oil lowers heart rate during submaximal exercise in elite Australian Rules footballers. *J Sci Med Sport* 2009; 12:503–507.
- Carter JR, Schwartz CE, Yang H, Joyner MJ. Fish oil and neurovascular control in humans. *Am J Physiol Heart Circ Physiol* 2012; 303:H450–H456.
- Cazzola R, Russo-Volpe S, Miles EA, Rees D, Banerjee T, Roynette CE, Wells SJ, Goua M, Wahle KWJ, Calder PC, Cestaro B. Age- and dose-dependent effects of an eicosapentaenoic acid-rich oil on cardiovascular risk factors in healthy male subjects. *Atherosclerosis* 2007; 193:159–167.
- Chin JP, Gust AP, Nestel PJ, Dart AM. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. *Hypertension* 1993; 21:22–28.
- Cobiac L, Clifton PM, Abbey M, Belling GB, Nestel PJ. Lipid, lipoprotein, and hemostatic effects of fish vs fish-oil n-3 fatty acids in mildly hyperlipidemic males. *Am J Clin Nutr* 1991; 53:1210–1216.
- Conquer JA, Cheryk LA, Chan E, Gentry PA, Holub BJ. Effect of supplementation with dietary seal oil on selected cardiovascular risk factors and hemostatic variables in healthy male subjects. *Thromb Res* 1999; 96:239–250.
- Croset M, Vericel E, Rigaud M, Hanss M, Courpron P, Dechavanne M, Lagarde M. Functions and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid. *Thromb Res* 1990; 57:1–12.
- Demque DM, Peters GR, Linet OI, Metzler CM, Klott KA. Effects of a fish oil concentrate in patients with hypercholesterolemia. *Atherosclerosis* 1988; 70:73–80.
- Derosa G, Cicero AFG, Fogari E, D'Angelo A, Bonaventura A, Romano D, Maffioli P. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. *J Clin Lipid* 2012; 6:553–564.
- Derosa G, Maffioli P, D'Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Gravina A, Mereu R, Randazzo S, Cicero AFG. Effects of long chain

- omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. *Expert Opin Pharmacother* 2009; 10:1239–1247.
26. Deslypere JP. Influence of supplementation with N-3 fatty acids on different coronary risk factors in men—a placebo controlled study. *Verh K Acad Geneesk Belg* 1992; 54:189–216.
  27. Dewell A, Marvasti FF, Harris WS, Tsao P, Gardner CD. Low- and high-dose plant and marine (n-3) fatty acids do not affect plasma inflammatory markers in adults with metabolic syndrome. *J Nutr* 2011; 141:2166–2171.
  28. Dyerberg J, Eskesen DC, Andersen PW, Astrup A, Buemann B, Christensen JH, Clausen P, Rasmussen BF, Schmidt EB, Tholstrup T, Toft E, Toubro S, Stender S. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. *Eur J Clin Nutr* 2004; 58:1062–1070.
  29. Finnegan YE, Minihane AM, Leigh-Firbank EC, Kew S, Meijer GW, Muggli R, Calder PC, Williams CM. Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. *Am J Clin Nutr* 2003; 77:783–795.
  30. Flaten H, Hostmark AT, Kierulf P, Lystad E, Trygg K, Bjerkedal T, Osland A. Fish-oil concentrate: effects on variables related to cardiovascular disease. *Am J Clin Nutr* 1990; 52:300–306.
  31. Geelen A, Zock PL, Swenne CA, Brouwer IA, Schouten EG, Katan MB. Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects. *Am Heart J* 2003; 146:E4.
  32. Ginty AT, Conklin SM. Preliminary evidence that acute long-chain omega-3 supplementation reduces cardiovascular reactivity to mental stress: a randomized and placebo controlled trial. *Biol Psychol* 2012; 89:269–272.
  33. Grimsgaard S, Bonna KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. *Am J Clin Nutr* 1998; 68:52–59.
  34. Gustafsson IB, Ohrvall M, Ekstrand B, Vessby B. Moderate amounts of n-3 fatty acid enriched seafood products are effective in lowering serum triglycerides and blood pressure in healthy subjects. *J Hum Nutr Diet* 1996; 9:135–145.
  35. Hallund J, Madsen BO, Bugel SH, Jacobsen C, Jakobsen J, Krarup H, Holm J, Nielsen HH, Lauritzen L. The effect of farmed trout on cardiovascular risk markers in healthy men. *Br J Nutr* 2010; 104:1528–1536.
  36. Harris WS, Lemke SL, Hansen SN, Goldstein DA, DiRienzo MA, Su H, Nemeth MA, Taylor ML, Ahmed G, George C. Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker. *Lipids* 2008; 43:805–811.
  37. Hellsten G, Boman K, Saarem K, Hallmans G, Nilsson TK. Effects on fibrinolytic activity of corn oil and a fish oil preparation enriched with omega-3-polyunsaturated fatty acids in a long-term study. *Curr Med Res Opin* 1993; 13:133–139.
  38. Hill AM, Buckley JD, Murphy KJ, Howe PRC. Combining fish-oil supplements with regular aerobic exercise improves body composition and cardiovascular disease risk factors. *Am J Clin Nutr* 2007; 85:1267–1274.
  39. Hughes GS, Ringer TV, Watts KC, DeLoof MJ, Francom SE, Spillers CR. Fish oil produces an atherogenic lipid profile in hypertensive men. *Atherosclerosis* 1990; 84:229–237.
  40. Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. *Am J Clin Nutr* 2007; 86:324–333.
  41. Knapp HR, FitzGerald GA. The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. *N Engl J Med* 1989; 320:1037–1043.
  42. Landmark K, Thaulow E, Hysing J, Mundal HH, Eritsland J, Hjermann I. Effects of fish oil, nifedipine and their combination on blood pressure and lipids in primary hypertension. *J Hum Hypertens* 1993; 7:25–32.
  43. Levinson PD, Iosiphidis AH, Saritelli AL, Herbert PN, Steiner M. Effects of n-3 fatty acids in essential hypertension. *Am J Hypertens* 1990; 3:754–760.
  44. Lofgren RP, Wilt TJ, Nichol KL, Crespin L, Pluhar R, Eckfeldt J. The effect of fish oil supplements on blood pressure. *Am J Pub Health* 1993; 83:267–269.
  45. Mackness MI, Bhatnagar D, Durrington PN, Prais H, Haynes B, Morgan J, Borthwick L. Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. *Eur J Clin Nutr* 1994; 48:859–865.
  46. Maki KC, Reeves MS, Farmer M, Griinari M, Berge K, Vik H, Hubacher R, Rains TM. Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. *Nutr Res* 2009; 29:609–615.
  47. McVeigh GE, Brennan GM, Cohn JN, Finkelstein SM, Hayes RJ, Johnston GD. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. *Arterioscler Thromb* 1994; 14:1425–1429.
  48. Meland E, Fugelli P, Laerum E, Ronneberg R, Sandvik L. Effect of fish oil on blood pressure and blood lipids in men with mild to moderate hypertension. *Scand J Prim Health Care* 1989; 7:131–135.
  49. Mills DE, Mah M, Ward RP, Morris BL, Floras JS. Alteration of baroreflex control of forearm vascular resistance by dietary fatty acids. *Amer J Physiol* 1990; 259:R1164–R1171.
  50. Mills DE, Prkachin KM, Harvey KA, Ward RP. Dietary fatty acid supplementation alters stress reactivity and performance in man. *J Hum Hypertens* 1989; 3:111–116.
  51. Monahan KD, Wilson TE, Ray CA. Omega-3 fatty acid supplementation augments sympathetic nerve activity responses to physiological stressors in humans. *Hypertension* 2004; 44:732–738.
  52. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. *Hypertension* 1999; 34:253–260.
  53. Mortensen JZ, Schmidt EB, Nielsen AH, Dyerberg J. The effect of N-6 and N-3 polyunsaturated fatty acids on hemostasis, blood lipids and blood pressure. *Thromb Haemost* 1983; 50:543–546.
  54. Mundal HH, Gjesdal K, Landmark K. The effect of N-3 fatty acids and nifedipine on platelet function in hypertensive males. *Thromb Res* 1993; 72:257–262.
  55. Murphy KJ, Meyer BJ, Mori TA, Burke V, Mansour J, Patch CS, Tapsell LC, Noakes M, Clifton PA, Barden A, Puddey IB, Beilin LJ, Howe PRC. Impact of foods enriched with n-3 long-chain polyunsaturated fatty acids on erythrocyte n-3 levels and cardiovascular risk factors. *Br J Nutr* 2007; 97:749–757.
  56. Neff LM, Culiner J, Cunningham-Rundles S, Seidman C, Meehan D, Maturi J, Wittkowski KM, Levine B, Breslow JL. Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults. *J Nutr* 2011; 141:207–213.
  57. Nestel P, Shige H, Pomeroy S, Cehun M, Abbey M, Raederstorff D. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. *Am J Clin Nutr* 2002; 76:326–330.
  58. Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. *Nutr Metab Cardiovasc* 2001; 11:7–16.
  59. Noreen EE, Brandauer J. The effects of supplemental fish oil on blood pressure and morning cortisol in normotensive adults: a pilot study. *J Compl Integr Med* 2012; 9:1–16.
  60. Passfall J, Philipp T, Woermann F, Quass P, Thiede M, Haller H. Different effects of eicosapentaenoic acid and olive oil on blood pressure, intracellular free platelet calcium, and plasma lipids in patients with essential hypertension. *Clin Investigator* 1993; 71:628–633.
  61. Prisco D, Paniccia R, Bandinelli B, Filippini M, Francalanci I, Giusti B, Giurlani L, Gensini GF, Abbate R, Neri Serneri GG. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. *Thromb Res* 1998; 91:105–112.
  62. Radack K, Deck C, Huster G. The effects of low doses of n-3 fatty acid supplementation on blood pressure in hypertensive subjects. A randomized controlled trial. *Arch Intern Med* 1991; 151:1173–1180.
  63. Ramel A, Martinez JA, Kiely M, Bandarra NM, Thorsdottir I. Moderate consumption of fatty fish reduces diastolic blood pressure in overweight and obese European young adults during energy restriction. *Nutrition* 2010; 26:168–174.
  64. Ryu J, Lerner J, Sullivan JM. Unresponsiveness of forearm hemodynamics to omega-3 polyunsaturated fatty acids and aspirin. *Prostaglandins* 1990; 39:339–347.
  65. Sagara M, Njelekela M, Teramoto T, Taguchi T, Mori M, Armitage L, Birt N, Birt C, Yamori Y. Effects of docosahexaenoic acid supplementation on blood pressure, heart rate, and serum lipids in scottish men

- with hypertension and hypercholesterolemia. *Int J Hypertens* 2011; 2011:1–7.
66. Sanders TA, Gleason K, Griffin B, Miller GJ. Influence of an algal triacylglycerol containing docosahexaenoic acid (22:6n-3) and docosapentaenoic acid (22:5n-6) on cardiovascular risk factors in healthy men and women. *Br J Nutr* 2006; 95:525–531.
67. Sjoberg NJ, Milte CM, Buckley JD, Howe PRC, Coates AM, Saint DA. Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation. *Br J Nutr* 2010; 103:243–248.
68. Stark KD, Holub BJ. Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy. *Am J Clin Nutr* 2004; 79:765–773.
69. Steiner A, Oertel R, Battig B, Pletscher W, Weiss B, Germinger P, Vetter W. Effect of fish oil on blood pressure and serum lipids in hypertension and hyperlipidaemia. *J Hypertens* 1989; 7:S73–S76.
70. Theobald HE, Goodall AH, Sattar N, Talbot DCS, Chowienczyk PJ, Sanders TAB. Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. *J Nutr* 2007; 137:973–978.
71. Toft I, Bonna KH, Ingebretsen OC, Nordoy A, Jenssen T. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. *Ann Intern Med* 1995; 123:911–918.
72. Vakhapova V, Richter Y, Cohen T, Herzog Y, Korczyn AD. Safety of phosphatidylserine containing omega-3 fatty acids in non-demented elderly: a double-blind placebo-controlled trial followed by an open-label extension. *BMC Neurol* 2011; 11:79.
73. Vandongen R, Mori TA, Burke V, Beilin LJ, Morris J, Ritchie J. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. *Hypertension* 1993; 22:371–379.
74. Vericel E, Calzada C, Chapuy P, Lagarde M. The influence of low intake of n-3 fatty acids on platelets in elderly people. *Atherosclerosis* 1999; 147:187–192.
75. von Houwelingen R, Nordoy A, van der Beek E, Houtsmuller U, de Metz M, Hornstra G. Effect of a moderate fish intake on blood pressure, bleeding time, hematology, and clinical chemistry in healthy males. *Am J Clin Nutr* 1987; 46:424–436.
76. Walser B, Stebbins CL. Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise. *Eur J Appl Physiol* 2008; 104:455–461.
77. Wang S, Ma AQ, Song SW, Quan QH, Zhao XF, Zheng XH. Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients. *Eur J Clin Nutr* 2008; 62:1426–1431.
78. Lindqvist HM, Langkilde AM, Undeland I, Sandberg AS. Herring (*Clupea harengus*) intake influences lipoproteins but not inflammatory and oxidation markers in overweight men. *Br J Nutr* 2009; 101:383–390.
79. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, Williams B, Ford GA. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens* 2006; 24:215–233.
80. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. *Circulation* 1993; 88:523–533.
81. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: meta-regression analysis of randomized trials. *J Hypertens* 2002; 20:1493–1499.
82. Mozaffarian D. Fish, n-3 fatty acids, and cardiovascular haemodynamics. *J Cardiovasc Med (Hagerstown)* 2007; 8:S23–S26.
83. Wang Q, Liang X, Wang L, Lu X, Huang J, Cao J, Li H, Gu D. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. *Atherosclerosis* 2012; 221:536–543.
84. Egert S, Stehle P. Impact of n-3 fatty acids on endothelial function: results from human interventions studies. *Curr Opin Clin Nutr Metab Care* 2011; 14:121–131.
85. Appel LJ, American Society of Hypertension Writing Group, Giles TD, Black HR, Izzo JL Jr, Materson BJ, Oparil S, Weber MA. ASH position paper: dietary approaches to lower blood pressure. *J Clin Hypertens (Greenwich)* 2009; 11:358–368.
86. Appel LJ, Miller ER 3rd, Seidler AJ, Whelton PK. Does supplementation of diet with “fish oil” reduce blood pressure? A meta-analysis of controlled clinical trials. *Arch Intern Med* 1993; 153:1429–1438.
87. Ruxton CHS. The benefits of fish consumption. *Nutr Bull* 2011; 36:6–19.
88. Adolphus K, Biac S. Oily fish consumption in young adults: current intakes, knowledge, barriers and motivations. *J Hum Nutr Diet* 2011; 24:375.